CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) shot up 2.7% during mid-day trading on Friday . The stock traded as high as $2.35 and last traded at $2.26. 2,686 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 33,735 shares. The stock had previously closed at $2.20.
Wall Street Analyst Weigh In
Separately, Benchmark reiterated a “speculative buy” rating and issued a $5.00 target price on shares of CytoMed Therapeutics in a report on Thursday, October 10th.
Check Out Our Latest Stock Analysis on GDTC
CytoMed Therapeutics Stock Performance
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Read More
- Five stocks we like better than CytoMed Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Disney’s Magic Strategy: Reinventing the House of Mouse
- The Role Economic Reports Play in a Successful Investment Strategy
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What is a Stock Market Index and How Do You Use Them?
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
